Robert A. Bradway
Net Worth
Last updated:
What is Robert A. Bradway net worth?
The estimated net worth of Mr. Robert A. Bradway is at least $192,792,449 as of 18 Feb 2021. He owns shares worth $113,934,535 as insider, has earned $4,367,914 from insider trading and has received compensation worth at least $74,490,000 in Amgen Inc..
What is the salary of Robert A. Bradway?
Mr. Robert A. Bradway salary is $5,730,000 per year as Chairman, Chief Executive Officer & Pres in Amgen Inc..
How old is Robert A. Bradway?
Mr. Robert A. Bradway is 62 years old, born in 1963.
What stocks does Robert A. Bradway currently own?
As insider, Mr. Robert A. Bradway owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Amgen Inc. (AMGN) | Chairman, Chief Executive Officer & Pres | 383,102 | $297.4 | $113,934,535 |
What does Amgen Inc. do?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Robert A. Bradway insider trading
Amgen Inc.
Mr. Robert A. Bradway has made 2 insider trades between 2012-2021, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 127,000 units of AMGN stock on 13 Apr 2020. As of 18 Feb 2021 he still owns at least 383,102 units of AMGN stock.
Amgen key executives
Amgen Inc. executives and other stock owners filed with the SEC:
- Dr. David M. Reese M.D. (62) Executive Vice President of R&D
- Mr. Esteban Santos (57) Executive Vice President of Operations
- Mr. Murdo Gordon (58) Executive Vice President of Global Commercial Operations
- Mr. Peter H. Griffith (66) Executive Vice President & Chief Financial Officer
- Mr. Robert A. Bradway (62) Chairman, Chief Executive Officer & Pres